Actress, author, podcaster, and mother of two, Busy Philipps is
teaming up with Supernus Pharmaceuticals to share her personal
journey with attention-deficit/hyperactivity disorder (ADHD) – one
of the most common psychiatric diagnoses in adults – as well as her
experience with Qelbree (viloxazine extended-release capsules), a
non-stimulant medication for the treatment of ADHD.3
Busy has been vocal about her personal experience living with
ADHD for years, but now she is revealing what it means to be a
woman navigating ADHD and wants other women who may be struggling
to know they are not alone. Boys are two times more likely than
girls to be diagnosed.4 While boys’ symptoms often fit the
stereotypical ideas of hyperactive ADHD, girls’ inattentive
symptoms are often overlooked. As a result, ADHD often goes
undiagnosed in young girls, leading to more adult females being
undiagnosed and therefore untreated – a sentiment reflective of
Busy’s own experience.2,5
“As women, we tend to mask or overcompensate for our ADHD
symptoms and end up working harder to get things done. With the
right medication, there’s a sense of relief for women with ADHD –
you’re suddenly able to take a deep breath," says Busy. "Since I
started treatment with Qelbree, I have been able to better manage
my ADHD symptoms and understand what to prioritize versus what can
be put on the backburner. I'm excited to collaborate with Supernus
as a woman navigating ADHD and shed light on the importance of
finding the right treatment by empowering others facing similar
challenges.”
The partnership comes just in time for Mental Health Awareness
Month, an important moment to raise awareness around mental health
conditions and overall wellness – including approximately 10
million adults living with ADHD in the United States.3
"Supernus seeks to encourage and lift up those living with ADHD
to talk to their doctor about managing and treating their
condition, especially during Mental Health Awareness Month,” says
Jack A. Khattar, President and Chief Executive Officer of Supernus
Pharmaceuticals. “We’re excited to see that more women with ADHD,
including Busy, are able to manage their ADHD symptoms with the
help of Qelbree.”
For more information about Qelbree, visit Qelbree.com. Patients
should speak to a doctor about all the medications they take, and
to see if Qelbree could be right for them.
INDICATIONQelbree® (viloxazine extended-release
capsules) is a prescription medicine used to treat ADHD in adults
and children 6 years and older.
IMPORTANT SAFETY INFORMATIONQelbree may
increase suicidal thoughts and actions, in children and adults with
ADHD, especially within the first few months of treatment or when
the dose is changed. Tell your doctor if you or your child have (or
if there is a family history of) suicidal thoughts or actions
before starting Qelbree. Monitor your or your child’s moods,
behaviors, thoughts, and feelings during treatment with Qelbree.
Report any new or sudden changes in these symptoms right
away.
You or your child should not take Qelbree if you or your
child:Take a medicine for depression called a monoamine
oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past
14 days. Also, you or your child should avoid alosetron,
duloxetine, ramelteon, tasimelteon, tizanidine, and
theophylline.
Qelbree can increase blood pressure and heart
rate. Your or your child’s doctor will monitor these vital
signs.
Qelbree may cause manic episodes in patients with
bipolar disorder. Tell your doctor if you or your child
show any signs of mania.
Do not drive or operate heavy machinery until you know
how Qelbree will affect you or your child. Qelbree may
cause you or your child to feel sleepy or tired.
The most common side effects of Qelbree in
patients 6 to 17 years are sleepiness, not feeling hungry, feeling
tired, nausea, vomiting, trouble sleeping, and irritability, and in
adults, insomnia, headache, sleepiness, tiredness, nausea,
decreased appetite, dry mouth, and constipation. These are not all
the possible side effects of Qelbree.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
1-800-FDA-1088.
Please see full Prescribing Information, including Boxed
Warning, for Qelbree here.
1Russell, J., et al. (2023). Number of ADHD Patients Rising,
Especially Among Women. Epic Research.2Holthe, M. E. G., Langvik,
E. (2017). The Strives, Struggles, and Successes of Women Diagnosed
with ADHD as Adults. SAGE Journals.3Culpepper, L., Mattingly, G.
(2010). Challenges in Identifying and Managing
Attention-Deficit/Hyperactivity Disorder in Adults in the Primary
Care Setting: A Review of the Literature. Primary Care Companion
Journal of Clinical Psychiatry.4Reuben C., Elgaddal N. (2024)
Attention-deficit/hyperactivity disorder in children ages 5–17
years: United States, 2020–2022. NCHS Data Brief, no 499.
Hyattsville, MD: National Center for Health Statistics.5Quinn, P.
O., Madhoo, M. (2014). A Review of Attention Deficit/Hyperactivity
Disorder in Women and Girls: Uncovering This Hidden Diagnosis. Prim
Care Companion CNS Disord.
About Supernus Pharmaceuticals,
Inc. Supernus Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments
for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease
(PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD
patients receiving levodopa-based therapy, and drug-induced
extrapyramidal reactions in adult patients. We are developing a
broad range of novel CNS product candidates including new potential
treatments for hypomobility in PD, epilepsy, depression, and other
CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEOTimothy C. Dec, Senior Vice
President and CFOSupernus Pharmaceuticals, Inc.Tel: (301)
838-2591
Or
INVESTOR CONTACT:
Peter VozzoICR WestwickeOffice: (443) 213-0505Email:
Peter.Vozzo@westwicke.com
MEDIA CONTACT:
Heidi Donato Tel: (516) 359-1146Email:
Heidi.Donato@bcw-global.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024